Search

Displaying results 3311 - 3320 of 5451 in total
  1. Drug

    Tirofiban

    go.drugbank.com/drugs/DB00775
    ApprovedInvestigational

    It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.

    Products: TIROFIBAN SOLUCION INYECTABLE 0.25 MG/ML, AGGRASTAT CONCENTRATE FOR INFUSION 0.25 mg/ml
  2. Drug

    19-Nor-5-androstenedione

    go.drugbank.com/drugs/DB01443
    ExperimentalIllicit

    It is regulated in the United States as a schedule III controlled substance, and prohibited by the World Anti-Doping Agency for use in competitive sports.

  3. Drug

    Romiplostim

    go.drugbank.com/drugs/DB05332
    ApprovedInvestigational

    Romiplostim is a thrombopoiesis stimulating dimer Fc-peptide fusion protein (peptibody) to increase platelet production through activation of the thrombopoietin receptor. The peptibody molecule has two identical single-chain subunits, ea...

  4. Drug

    Ritodrine

    go.drugbank.com/drugs/DB00867
    ApprovedWithdrawn

    Adrenergic beta-agonist used to control premature labor.

    Products: PRE-PAR 50 MG/5 ML IM/IV ÇÖZELTİ İÇEREN AMPUL, 1 AMPUL
  5. Drug

    Albumin human

    go.drugbank.com/drugs/DB00062
    ApprovedInvestigational

    It binds to water, cations (such as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals (including barbiturates). … This is a biosimilar drug to existing human serum albumin and was approved for a biological license at both 5% and 25% concentrations by the FDA on June 21, 2018 [L3101].

    Products: NANO-ALBUMON® 1 MG, Octagam 100 mg/ml Infusionslösung
  6. Drug

    Vedolizumab

    go.drugbank.com/drugs/DB09033
    ApprovedInvestigational

    [A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter.

    Products: ENTYVIO® 108 MG SOLUCIÓN INYECTABLE, ENTYVIO® (SUBCUTÁNEO) VEDOLIZUMAB 108 MG SOLUCIÓN INYECTABLE
  7. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749

    Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-Carboxylate
  8. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

    Products: NEOSTIGMINA 0.5 MG/ ML, NEOSTIGMINA 0.5 MG/ML.
  9. Drug

    Mersalyl

    go.drugbank.com/drugs/DB09338
    Experimental

    Interestingly, it has been found to have antiviral properties in mice [L1584]. … It is an outdated drug, and its approval has been discontinued by the FDA. Mersalyl acid is currently replaced by less toxic non-mercury containing diuretics [L1575, L1577].

  10. Drug

    Efzofitimod

    go.drugbank.com/drugs/DB16453
    Investigational

    It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.